Cellivery Registers Parkinson's Disease Treatment Drug Patents in Succession... "Completed in Korea and Canada"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 14th that its Parkinson's disease treatment new drug iCP-Parkin has been granted patents in Canada and Korea after more than two years of examination, recognizing its novelty and inventive step.

A company official stated, "The iCP-Parkin, for which the patent registration has been completed this time, is a new drug for Parkinson's disease treatment. It has been filed for patents in 34 major countries worldwide, including the United States and the 27 countries of the European Union, and among them, we succeeded in patent registration in North America, where examination is the most stringent and registration is difficult. We have also succeeded in patent registration in 32 countries including the European Union, Australia, and Asia, and the final examination is underway in China and India, the two most populous countries in the world," he said.

In particular, the success of patent registration in Canada will be a great advantage in licensing (L/O) negotiations with global pharmaceutical companies based in North America, which accounts for the largest portion of the pharmaceutical market, as well as global pharmaceutical companies seeking licensing rights in the North American region. The company explained that this means securing patent rights for 74% of the global pharmaceutical market, or three-quarters of it.

So far, Cellivery holds a total of 19 intellectual property rights, including 5 patents for the original technology, the pharmacological substance in vivo delivery technology TSDT platform (Japan, USA, Canada, Korea, Australia), 1 patent for pancreatic cancer anticancer drug (USA), 1 patent for liver cancer anticancer drug (USA), 6 patents for Parkinson's disease treatment new drug (Japan, USA, Canada, Korea, European Union, Australia), 1 patent for bone formation promoter biobetter (USA), 1 patent for severe obesity treatment drug (USA), 2 patents for genome editing technology (USA, Europe), and 2 patents for induced pluripotent stem cell production technology (USA, Europe).

CEO Daewoong Cho emphasized, "Patents and academic papers are the most critical evaluation criteria for licensing with global pharmaceutical companies and the foundation of our business. We have secured the first and second requirements, patent rights and internationally recognized academic papers, and based on these, the results of feasibility tests conducted directly by global pharmaceutical companies will determine the scale of the final deal to be concluded."

This content was produced with the assistance of AI translation services.